Platelet Tissue Factor Synthesis in Type 2 Diabetic Patients Is Resistant to Inhibition by Insulin
Anja J. Gerrits, Cornelis A. Koekman, Timon W. van Haeften, and Jan Willem N. Akkerman

OBJECTIVE—Patients with type 2 diabetes have an increased risk of cardiovascular disease and show abnormalities in the coagulation cascade. We investigated whether increased synthesis of tissue factor (TF) by platelets could contribute to the hypercoagulant state.

RESEARCH DESIGN AND METHODS—Platelets from type 2 diabetic patients and matched control subjects were adhered to different surface-coated proteins, and TF premRNA splicing, TF protein, and TF procoagulant activity were measured.

RESULTS—Different adhesive proteins induced different levels of TF synthesis. A mimetic of active clopidogrel metabolite (AR-C69931 MX) reduced TF synthesis by 56 ± 10%, an aspirin-like inhibitor (indomethacin) by 82 ± 9%, and the combination by 96 ± 2%, indicating that ADP release and thromboxane A₂ production followed by activation of P2Y12 and thromboxane receptors mediate surface-induced TF synthesis. Interference with intracellular pathways revealed inhibition by agents that raise cAMP and interfere with phosphatidylinositol 3-kinase/protein kinase B. Insulin is known to raise cAMP in platelets and inhibited collagen III–induced TF premRNA splicing and reduced TF activity by 35 ± 5 and 47 ± 5% at 1 and 100 nmol/L. Inhibition by insulin was reduced in type 2 diabetes platelets resulting in an ~1.6-fold higher TF synthesis than in matched control subjects.

CONCLUSIONS—We characterized the extra- and intracellular mechanisms that couple surface activation to TF synthesis in adhering platelets. In healthy individuals, TF synthesis is inhibited by insulin, but in patients with type 2 diabetes insulin inhibition is impaired. This leads to the novel finding that platelets from type 2 diabetic patients produce more TF than platelets from matched control subjects. Diabetes 59:1487–1495, 2010
of proteins including TF, make them a source for TF synthesis. In the present study, we investigated how contact with adhesive proteins initiates platelet TF synthesis and studied a possible interference by insulin in healthy individuals and type 2 diabetic patients.

RESEARCH DESIGN AND METHODS

We obtained human recombinant insulin (solubilized according to the recommendations of the manufacturer in 10 mmol/l acetic acid, 100 mmol/l NaCl, and 0.01% BSA to a stock concentration of 100 μmol/l); wortmannin; 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-9); LPS (E. coli 0111:B4); indomethacin; puromycin; collagen types I and III; ADP from Sigma (St. Louis, MO); Akt inhibitor 1701-I from Biovision (Mountain View, CA); iloprost from Schering (Berlin, Germany); forskolin, BAPTA(AM), ionophore A23187, Tg003, and cantharidin from Calbiochem (La Jolla, CA); LY294002 from Biomol (Plymouth Meeting, PA, USA); cycloheximide from MP Biomedicals (Santa Ana, CA, USA); collagen reagent Horm from Nycomed Pharma; a mixture of 95% type I and 5% type III collagen (Munich, Germany); thrombin and fibrinogen from Enzyme Research Laboratories (South Bend, IN); and U-44619 from Cayman Chemicals (Ann Arbor, MI). Plasma-derived VWF was purified from VWF/FVIII concentrate (Hemate P; Behring, Marburg, Germany) (18). Factor X (FX) was purified from fresh-frozen plasma (19). Recombinant FVIII (rFVIII) was from Novo Nordisk ( Bagsvaerd, Denmark), and recombinant TF (Innovin) was from Dade Behring (Liederbach, Germany). Antibodies against the horseradish peroxidase−labeled anti-rabbit antibody were from Cell Signaling Technology (Danvers, MA), anti-phospho-Ser polyclonal antibody was from Upstate Biotechnology (Bucks, U.K.), peroxidase-linked goat anti-mouse antibody was from DAKO (Carpinteria, CA), anti-splicing factor 2 (SF2)/−alternative splicing factor (ASF) antibody was from Abcam (Cambridge, U.K.), anti-TF antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA) for immunoprecipitation and Affinity Biologicals (Ancester, ON, Canada) for Western blotting, and anti-TF pathway inhibitor (TFPI) antibody from American Diagnostica (Stamford, U.K.) An inhibitory antibody against TF was a generous gift from Dr. M. Kjalke (Hemostasis Biology, Novo Nordisk, Malov, Denmark). The ADP receptor blocker 8 (range).

The study had been approved by the medical ethical review board. Type 2 diabetic subjects were recruited from the outpatient clinics of the Utrecht Medical University Hospital (Utrecht, the Netherlands). All patients were anti-GAD negative and had plasma C-peptide levels >0.30 nmol/l. We recruited (baseline, Swing patients) in order to circumvent the possibility that oral hypoglycemic agents interfere with the study; only metformin use was acceptable (it was stopped the evening for the study). Six patients used four injections with insulin per day, one used continuous subcutaneous insulin infusion. Their further characteristics are given in Table 1. Patients and matched control subjects gave their informed consent prior to participation in the study.

Platelet isolation. Freshly drawn venous blood from healthy volunteers and type 2 diabetic patients was collected into 0.1 volume of 130 mmol/l Na3 citrate. Platelets were isolated as described (11). Attempts to remove contaminating monocytes included 1) incubation of a platelet suspension (2×108 platelets/ml) with either anti-CD14 antibody− or anti-CD45 antibody−coupled beads (15 min, 22°C, 35 µl anti-CD14 or anti-CD45 beads per 40×108 platelets) and subsequent magnetic separation (Miltenyi Biotec, Bergisch Gladbach, Germany) and 2) a double incubation of a concentrated platelet suspension (−15×108 platelets/ml) with a cocktail of anti-CD14 antibody− and anti-CD45 antibody−coupled beads (15 min, 22°C, 35 µl anti-CD14 and 35 µl anti-CD45 beads per 40×108 platelets) and magnetic separation. Contamination with monocytes was monitored by RT-PCR of CD14 mRNA. To this end, total RNA was isolated using the kit from RNA-Bee (Tell Tech, Friendswood, TX), and RT-PCR was performed using the forward primer 5′-AAAGCACTTCCAGAGCTGTC-3′ and the reverse primer 5′-TC GAGCGTCAGTTCCTTGAGG-3′ on a PTC-200 apparatus (MJ Research, Waltham, MA).

TF expression. To investigate TF synthesis in platelets, an aliquot of suspension (2×108 platelets) was incubated for static adhesion experiments in six-well plates (Corning ultra-low attachment surface; Corning, Acton, MA) or kept in suspension for the indicated times at 37°C. Wells were coated with 50 µg/ml hrom collagen, 50 µg/ml collagen type I, 50 µg/ml collagen type III, 1 unit/ml thrombin, 100 µg/ml fibrinogen, and 10 µg/ml VWF for 2 h at 37°C. For analysis of TF procoagulant activity, adhered platelets, collected in 250 µl HEPES/Tyrode buffer, or suspensions were lysed by freeze/thawing three times and centrifuged (1620g, 2 min, 22°C). Pellet fractions were dissolved in 50 µl HEPES/Tyrode buffer. Samples were incubated with 2 µg/ml anti-TFPI antibody (15 min, 22°C) and thereafter with 10 µg/ml FX, 5 units/ml rFVIII, and 5 mmol/l CaCl2 (45 min, 37°C). FXa generation was measured in a fluorescence reader at 405 nm after addition of Fxa substrate (Pentapharm, Basel, Switzerland). Procoagulant activity was determined based on a standard curve derived from serial dilutions of recombinant TF.

For analysis of splicing of TF premRNA, 12×108 platelets were adhered to a coated surface or kept in suspension, as indicated. Total RNA was isolated (RNA-Bee; Tell Tech), and RNA levels adjusted for variations per sample (by

---

**TABLE 1**

Characteristics of the study population

|                         | Control group | Type 2 diabetic patients | P     |
|-------------------------|---------------|--------------------------|-------|
| n                        | 8             | 8                        |       |
| Age (years)             | 52 ± 3        | 58 ± 3                   | 0.2   |
| BMI (kg/m²)             | 25 ± 0.9      | 28 ± 2                   | 0.2   |
| Systolic blood pressure (mmHg) | 140 ± 7      | 131 ± 3                  | 0.2   |
| Diastolic blood pressure (mmHg) | 86 ± 4       | 80 ± 4                   | 0.3   |
| HbA1C (%)               | 5.5 ± 0.09    | 7.3 ± 0.5                | 0.002 |
| Cholesterol (mmol/l)    | 6.1 ± 0.4     | 4 ± 0.3                  | 0.001 |
| Triglycerides (mmol/l)  | 1.7 ± 0.3     | 1.9 ± 0.4                | 0.6   |
| HDL cholesterol         | 1.3 ± 0.07    | 1.1 ± 0.11               | 0.2   |
| Creatinine (µmol/l)     | 95 ± 6.4      | 104 ± 6                  | 0.3   |
| Management with insulin | 8             | 8                        |       |
| Duration of diabetes (years) | 16 ± 2      | 16 ± 2                   |       |
| C-peptide (µmol/l)      | 0.74 ± 0.14 (0.34–1.64) | 0.72 ± 0.07 (0.39–1.05)  | 0.9   |
| Smoking                 | 3             | 3                        |       |
| Medication              |               |                          |       |
| Aspirin                 | 0             | 0                        |       |
| Statin                  | 5             | 5                        |       |
| ACE inhibitor or angiotensin receptor blocker | 8 | 8 |       |
| Cardiovascular disease  | 2             | 2                        |       |

Data are means ± SE or means ± SE (range).
measuring the optical density OD250 on a NanoDrop spectrophotometer), and RT-PCR was performed on a PCR apparatus (PTC-200; MJ Research) using primers that overlapped intron 4, with forward primer 5'-CTCGACAGACCA CAATTCAG-3' and reverse primer 5'-CGGCTGCTGTAACCTTCCTC-3'.

Alkaline phosphatase assay. The number of adhered platelets was inferred from the content of alkaline phosphatase in collected samples, as published (20). Alkaline phosphatase activity was related to platelet number using a serial dilution of platelets in suspension.

Immunoprecipitation, SDS-PAGE, and Western blotting. To determine levels of TF protein and the Ser phosphorylation of SF2, aliquots of 2 × 10^9 platelets were adhered to a coated surface in six-well plates or kept in suspension (1 h, 37°C). Adhered platelets and suspensions were collected in lysis buffer (1% NP40, 0.5% octylglucoside, 0.1% SDS, and 5 mM EDTA in PBS) supplemented with 10% protease inhibitor cocktail, 1 mM/l NaVO₃, and 10 μg/ml cantharidin. Proteins were precipitated with protein G-Sepharose in combination with 1 μg/ml anti-TF or anti-SF2 antibody overnight at 4°C. Precipitates were washed three times and dissolved in Laemmli sample buffer.

Proteins were analyzed by SDS-PAGE and Western blotting. After blocking with Odyssey buffer (1 h, 22°C), membranes were incubated (16 h, 4°C) with 1 μg/ml anti-TF, anti–phospho-Ser, or anti-SF2 antibody. Immunoblots were visualized using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE) and Alexa-labeled antibodies according to the manufacturer’s instructions. The intensity of the bands was quantified with ImageJ software.

RESULTS
Preparation of pure platelet suspensions. Since monocytes have a much higher capacity to synthesize TF than platelets, it was essential to prepare pure platelet suspensions. Platelet preparations prepared by conventional centrifugation/resuspension (7,11) without and with treatment with anti-CD45 magnetic beads were positive for the monocyte marker CD14 detected by RT-PCR (Fig. 1A, top panel). Pure preparations were obtained by a double incubation of concentrated suspensions with anti-CD14/CD45 magnetic beads and monocyte removal by magnetic sorting. After 35 cycles, RT-PCR of CD14 was negative in the platelet preparation and positive in the eluate (Fig. 1A, bottom panel). Upon stimulation with LPS, CD14-mRNA-containing suspensions adhering to fibrinogen synthesized TF activity detected in the FXa assay, but CD14-mRNA-negative preparations did not (Fig. 1B). To ensure purity of platelet suspensions, a sample of adhered platelets with LPS was included in all experiments, and series with LPS-induced TF synthesis were discarded. Addition of anti-TF antibody (0.5 μg/ml, 15 min, 22°C) completely blocked TF activity in activated platelets confirming specificity of the FXa assay.

Activated platelets express TF by splicing of premRNA. TF synthesis and TF premRNA splicing were studied on fibrinogen- and collagen-coated surfaces. Platelets adhering to a fibrinogen-coated surface (4 h, 37°C) synthesized 0.24 ± 0.04 ng TF/2 × 10^9 platelets (n = 10). TF synthesis in adhered platelets was inhibited by the translation blockers cycloheximide (58 ± 2%, n = 3) and puromycin (76 ± 6%, n = 12) and the splicing blocker Tg003 (51 ± 7%, n = 6) (Fig. 1C), confirming earlier work (17,21). To demonstrate splicing of TF premRNA, an RT-PCR with primers overlapping intron 4 was performed on platelets adhered to collagen type I (2 h, 37°C). The result showed the expected band for spliced mRNA at 297 bp and for unspliced mRNA at 904 bp in the presence of Tg003 (Fig. 1D). Regulation of TF premRNA splicing was examined by measuring the Ser phosphorylation of SF2, an effector of Cdc2-like kinase (Cdk-1) (Fig. 1E). The low levels of SF2-Ser phosphorylation in platelets in suspension were unchanged after stimulation with thrombin and increased when platelets had adhered to fibrinogen (4 h, 37°C). Tg003 reduced the phosphorylation, confirming its dependence on Cdk-1. These results confirm that adhering platelets synthesize TF through splicing of premRNA.

Different splicing at different adhesive surfaces. The question was addressed regarding which adhesive surface induced the highest TF premRNA splicing. Puromycin was used to separate translation-dependent TF activity from background TF. TF synthesis on horn collagen, collagen I, and thrombin was 0.34 ± 0.10, 0.32 ± 0.07, and 0.30 ± 0.05%, respectively. A lower TF activity was found on fibrinogen (0.24 ± 0.04), collagen III (0.17 ± 0.02%), and VWF (0.09 ± 0.03%) (n = 4) (Fig. 2A). Since different adhesive surfaces induced different extents of adhesion/aggregation, bound platelets were quantified on the basis of alkaline phosphatase content. The highest adhesion/aggregation was found with collagen III, collagen I, and horn collagen (~125 × 10^6 platelets), whereas adhesion to thrombin, fibrinogen, and VWF was ~30% lower (Fig. 2B). Expression per platelet and correction for background TF (defined as ΔTF activity), indicated that horn collagen, thrombin, and collagen I induced the highest TF synthesis followed by fibrinogen, collagen III, and VWF (Fig. 2C). Further experiments were based on collagen III, because it induced the highest platelet adhesion and is present in the vasculature. We examined whether adhered platelets produce more TF than platelets in suspension. Collagen III–adhered platelets (4 h, 37°C) produced 600fold more TF than platelets in suspension stimulated with collagen III (0.17 ± 0.09 and 0.0003 ± 0.0001 ng TF/2.0 × 10^9 platelets, respectively, n = 3), indicating that splicing of TF premRNA is strongly facilitated by adherence to a surface (Fig. 2D), in contrast with an earlier finding (17,21).

Inhibition of platelet TF synthesis. To examine the mechanisms that couple surface activation to TF synthesis, platelets were adhered to collagen III without and with coincubation with AR-C69931 MX (which mimics blockade of the P2Y12 receptor by the active metabolite of clopido
grel), with indomethacin, an easily soluble COX-1 inhibitor which mimics the action of aspirin, or a combination. The inhibitors did not change platelet adhesion during prolonged contact with collagen III (Fig. 3A, insert). AR-C69931 induced a 56 ± 16% decrease in TF synthesis, indicating that in its absence TF synthesis is enhanced by ADP secretion and P2Y12 receptor–mediated signaling. Indomethacin induced an even steeper reduction and inhibited TF synthesis by 82 ± 9%. The combination of the two inhibitors reduced TF synthesis by 96 ± 2% (n = 4, Fig. 3A). Thus, platelet TF synthesis strongly depends on the extracellular feedback loops mediated by secretion of granule ADP and release of thromboxane A2 (TXA2).

There was little effect of metabolic inhibitors on adhe-
sion (not shown). The adenyl cyclase activator forsko-
lin and the stable prostaglandin mimetic iloprost raise cAMP and inhibited TF synthesis on collagen III by 51 ± 14 and 82 ± 6%, respectively. BAPTA/AM, which lowers the cytosolic Ca²⁺ concentration and quenches Ca²⁺ increases in activated platelets, inhibited TF synthesis almost completely. Incubation with ionophore A23187 alone did not change collagen III–induced TF synthesis, but coincubation with 1 mM/l Ca²⁺ increased TF synthesis to 443 ± 57%. Inhibitors of P3-K (wortmannin, LI294002) and PKB (Akt inhibitor 1701-1, ML-9) decreased TF synthesis by ≥60%, indicating that in the absence of inhibitors, the P3-K/PKB pathway signals to TF premRNA via a PI3-K/PKB pathway signals to TF premRNA via a PI3-K/PKB pathway signals to TF premRNA.
FIG. 1. Platelet-specific splicing of TF premRNA and TF synthesis. A: Detection of leukocyte-specific CD14 RNA (422 bp) in monocytes (lane 1), platelet suspensions prepared by conventional centrifugation/resuspension (lane 2), leukocyte-depleted (depl) platelet suspensions obtained by incubation with either anti-CD14 or anti-CD45 magnetic beads (lane 3, top panel), or double incubation with anti-CD14 and anti-CD45 magnetic beads (lane 3, bottom panel) and elution (lane 4, leucocyte-rich fraction). Controls RT and RNA show the presence of genomic DNA and the specificity of the PCR (5,6). B: Lack of LPS-induced TF synthesis in CD14 mRNA-negative suspensions. CD14 mRNA-positive and CD14 mRNA-negative platelet (plt) suspensions without (H) and with (f) 1 μg/ml LPS. Incubation with a blocking antibody against TF completely inhibited TF activity in CD14 mRNA-negative suspensions. TF activity in fibrinogen-adhered platelets without LPS stimulation was expressed as 100%. C: TF activity in fibrinogen-adhered platelets (4 h, 37°C, □) is inhibited by the translation blockers cycloheximide and puromycin and the splicing blocker Tg003 (in DMSO, ▪). D: Splicing by platelets adhering to collagen I (col I) (4 h, 37°C) demonstrating a shift from premRNA (904 bp) to mature mRNA (297 bp). E: Negative SF2 phosphorylation in resting and thrombin (thr)-stimulated platelet suspensions and positive SF2 phosphorylation in fibrinogen-adhered platelets, which is inhibited by Tg003. Data are means ± SE. n = 3–12. A, D, and E: representative examples for n = 3.
splicing (Fig. 3B). To investigate whether the inhibitors interfere with release of ADP/TxA₂ and/or with signaling from ADP/TxA₂ receptors to the spliceosome, experiments were repeated in the presence of excess of ADP (50 μmol/l) and of the stable TxA₂ analog U-46619 (2 μmol/l). Inhibition of TF synthesis by the metabolic inhibitors was preserved, indicating that in addition to the known suppression of ADP/TxA₂ release, these blockers interfere with the control of TF premRNA splicing (Fig. 3C). Western blot analysis confirmed that iloprost inhibited synthesis of TF protein (Fig. 3D). Together, these data reveal that surface-induced TF synthesis is inhibited by a rise in cAMP strongly depends on cytosolic Ca²⁺ and is induced by signaling through the PI3-K/PKB pathway.

**Insulin inhibits collagen-induced TF synthesis in platelets.** Since surface-induced TF synthesis was sensitive to agents that raise cAMP or inhibit the PI3-K/PKB pathway, we addressed the question whether insulin interferes with adhesion-induced TF synthesis. Platelets were preincubated with 100 nmol/l insulin (5 min, 37°C) and adhered to different adhesive surfaces. The degree of inhibition differed between adhesive proteins and reached 94 ± 6, 64 ± 27, 76 ± 27, 67 ± 14, and 41 ± 7% (n = 5) for horn collagen, thrombin, collagen I, fibrinogen, and collagen III, respectively. On VWF, no inhibition by insulin was found (Fig. 4A). To elucidate whether insulin interferes with splicing before or after release of ADP/TxA₂, experiments were repeated in the presence of excess of ADP and TxA₂ mimetic. Inhibition of collagen III–induced TF synthesis by insulin in normal subjects (59 ± 12%, n = 8; P < 0.05 with Mann-Whitney U test; Fig. 4D). In type 2 diabetic patients, collagen III–induced TF activity inhibition by insulin was lost, resulting in higher levels of collagen III–induced TF activity (96 ± 12%, n = 8) compared with matched control subjects (59 ± 12%, n = 8).

**DISCUSSION**
Novel findings in the present study are 1) the identification of the extra- and intracellular mechanisms that couple surface activation to initiation of TF synthesis in platelets, 2) the inhibition of TF synthesis by insulin in normal platelets, and 3) the loss of insulin inhibition in platelets
from patients with type 2 diabetes resulting in a 1.6-fold–
higher TF synthesis. The increased TF synthesis might be
a cause of the hypercoagulant state observed in type 2
diabetic patients and contribute to the increase in throm-
botic risk.

The presence of TF synthesis in platelets is controver-
sial. Some investigators attributed a positive outcome to
contamination with monocytes, which have a many-fold–
higher translation capacity (22–24). Therefore, we in-
cluded a purity check in every experiment to demonstrate
unequivocally that platelets synthesize TF. The CD14
mRNA–free platelet suspensions showed no TF premRNA
splicing upon stimulation with LPS, which is a potent
inducer of TF synthesis in monocytes (16). Apparently,
splicing of TF premRNA is not under control of the platelet
LPS receptor, which contrasts with other studies that
show LPS-induced splicing of interleukin (IL)-1β and
cyclooxygenase (COX)-2 premRNA in platelets (25).

Platelets adhering to surface-coated adhesive proteins
start splicing of TF premRNA and synthesis of TF protein
and induce the capacity to initiate coagulation, confirming
earlier observations (17,21). The anucleate platelet has

---

**FIG. 3. Effect of inhibitors of signaling pathways on TF synthesis in platelets.**

**A:** Platelets were preincubated with a mimetic of active clopidogrel metabolite (AR-C69931 MX, AR, 250 nmol/l), the aspirin-like inhibitor indomethacin (Indo, 100 μmol/l) or the combination (15 min, 37°C). AR-C69931 MX and indomethacin did not affect platelet adhesion (*insert*) but reduced surface-induced TF synthesis (4 h, 37°C). **B:** Platelets were preincubated with the adenylyl cyclase activator forskolin (40 μmol/l), the stable prostacyclin mimetic iloprost (1 μg/ml), the Ca²⁺ quencher BAPTA/AM (25 μmol/l), ionophore A23187 (12 μmol/l) in the absence and presence of CaCl₂ (1 mmol/l), the PI3-K/PKB inhibitors wortmannin (0.5 μmol/l) and LY294002 (10 μmol/l), the Akt inhibitor 1701-1 (2 μmol/l), and ML-9 (100 μmol/l) (15 min, 37°C). The inhibitors reduced the surface-induced TF synthesis (4 h, 37°C). Addition of vehicle alone did not change surface-induced TF levels (as shown in Fig. 1C). **C:** Platelets in the presence of excess of ADP and the TxA₂ mimetic U-44619 were preincubated with iloprost, BAPTA/AM, wortmannin, LY294002, the Akt inhibitor 1701-1, and ML-9 before platelets were adhered to collagen III (4 h, 37°C) and TF activity was determined. **D:** Platelets were adhered to fibrinogen (4 h, 37°C). The blot shows the 60-kDa band (in the presence of DTT) of monocyte (mono) TF, surface-induced platelet TF protein, the inhibition by puromycin (puro), and by the cAMP-raising agent iloprost (ilo). **A–C:** Representative example for n = 3. *A–C: TF activity in collagen III–adhered platelets was expressed as 100%. Data are means ± SE. n = 3–4. *Denotes a significant difference, P < 0.05. ns, not significant.
long been considered incapable of synthesizing proteins. Introns removal was thought to be confined to the nucleated megakaryocyte and platelet proteins to be the exclusive result of transcription and translation in this progenitor cell (26). Unexpectedly, the platelet cytoplasm SF2/ASF, a regulator of constitutive and alternative splicing (27) together with a number of premRNAs with message for IL-1β, B-cell lymphoma 3, plasminogen activator inhibitor-1, COX-2, and TF (28–30). Platelets stimulated with soluble agonists or adhering to fibrinogen formation of mature RNAs and translation into functional proteins. Splicing of TF premRNA results in formation of TF protein and the capacity to start coagulation and is under control of dual specificity Clk-1, which contains an NH2-terminal region enriched in serine/arginine dipeptides (SR) that interacts with SF2/ASF (31). Inhibition of splicing by Tg003 and of protein synthesis by puromycin confirm that platelets are capable of transcription/translation-dependent TF synthesis (17). However, the inhibition was incomplete, suggesting that platelets contain a small store of encrypted TF that becomes active when the cells adhere to an adhesive surface.

Splicing of TF premRNA was 600-fold more efficient in adhering platelets than in platelet suspensions, suggesting...
that close contact between platelets accelerates this process. In adhered platelets, the P2Y12 receptor blocker AR-C69931 MX inhibited TF synthesis by 56% and the COX-1 blocker indomethacin by 82%, illustrating that without inhibitors, TF synthesis is strongly enhanced by ADP secretion and TxA2 formation and subsequent activation of the P2Y12 receptor (ADP) and TPαβ receptors (TxA2). The combination of the blockers reduced TF synthesis almost by 100%. This observation might indicate that in vivo signaling to TF premRNA splicing is inhibited by the active clopidogrel metabolite as well as aspirin and that the combination abolishes the major part of platelet TF production. Apparently, there is little TF synthesis in the absence of feedback activation by released ADP and TxA2, indicating that surface receptors that trigger TF premRNA splicing predominantly do so by inducing these positive feedback pathways. Collagen I, hrom collagen, and thrombin had the strongest capacity to induce splicing of TF premRNA. Fibrinogen and collagen III induced less splicing, and VWF was the weakest activator. These differences might reflect the contribution of ADP/TxA2 release in platelet activation by these agonists, which is strong in hrom collagen (32) and thrombin (33) activation, weak in activation by surface-coated fibrinogen (34), and virtually absent in platelet activation by coated VWF (35).

Iloprost, BAPTA-AM, and inhibitors of PI3-K/PKB inhibited surface-induced TF synthesis, indicating that negative control through cAMP-dependent mechanisms and positive control through the PI3-K/PKB route determine the rate of TF synthesis. In addition to a direct effect of these inhibitors on the release of ADP/TxA2, inhibition of TF activity also takes place after the released products start further signaling through the P2Y12 and TxA2 receptors. Protein kinase A (PKA) and PKB are activated by an increase in cAMP concentration induced by forskolin or 8-CPT-cAMP and phosphorylate SR proteins in vitro and change splice site selection in vivo (36). PKB contributes to phosphorylation of SR proteins, specifically SFP2 (37), which potentiate their binding to recently transcribed mRNA and/or directly stimulate SR protein activities. Interestingly, in monocytes, TF expression is under negative control by the PKB pathway (16,38). Here, PKB inhibits nuclear factor-kB activity (38), such in contrast to anucleated platelets where PKB regulates the splicing mechanism.

The induction of ADP/TxA2 release followed by signaling from ADP/TxA2 receptors to the spliceosome is under control of insulin. In normal platelets, insulin interferes with the P2Y12 pathway by inducing the association of IRS-1 with Gβγ, thereby blocking G-mediated cAMP suppression, which attenuates platelet functions. In addition, insulin stimulates the PI3-K/PKB pathway, initiating glucose uptake through upregulation of GLUT3 transporters (7,13). Interference with cAMP suppression by insulin impairs agonist-induced Ca2+ rises, aggregation, secretion, and the generation of a procoagulant surface, and the interference with TF synthesis presented here adds to the list of platelet functions under negative control by insulin.

Platelet TF does not seem to play a role in acute injury, since it takes long to express active TF. An animal model of laser-induced vessel-wall injury (14) shows the first appearance of TF at ~100 s after induction of vessel wall damage, which is well before the first sign of platelet TF synthesis. Diabetes increases the risk of developing lower-extremity arterial disease, which is one of the first signs of a generalized atherosclerotic disease (39). A key event in the pathogenesis of type 2 diabetes is loss of atherosclerotic plaque stability. When the fibrous cap is disrupted, a platelet plug forms, which continuously increases in size until the lumen is completely obstructed. In the chronic process of arterial occlusive disease, the slow but consistent production of TF by platelets may well contribute to the propagation and stabilization of a thrombus. Indeed, previous studies have detected TF antigen and activity in the atherosclerotic plaque (40). The elevated TF synthesis in platelets form type 2 diabetic patients might result in a more stable clot inducing occlusion of an artery at sites where atherosclerotic lesions have developed.

ACKNOWLEDGMENTS

This work was supported by the Dutch Diabetes Research Foundation (no. 2004.00.029) and the Netherlands Thrombosis Foundation (2006-1).

No potential conflicts of interest relevant to this article were reported.

The authors acknowledge the cooperation of the patients and control subjects.

REFERENCES

1. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI. Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002;105:2231–2259

2. Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GD, Small M. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992;41:909–913

3. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Solbel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104–109

4. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:41–54

5. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004;109:2519–2528

6. Sambola A, Osende J, Haticeck J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003;107:973–977

7. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, Akkerman JM. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417–422

8. Angiolillo DJ, Bernardi E, Ramire C, Costa MA, Sabate M, Jimenez-Quevedo F, Hernandez R, Moreno R, Escaned J, Alfonso F, Bello M, Bass TA, Macaya C, Fernandez-Ortiz A. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antplatelet treatment. J Am Coll Cardiol 2006;48:208–204

9. Trovati M, Anfossi G, Cavafol F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1994;43:104–109

10. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, Piretto V, Cavafol F, Anfossi G. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995;44:1318–1322

11. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004;279:3254–3264

12. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, Piretto V, Cavafol F, Anfossi G. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995;44:1318–1322

13. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004;279:3254–3264

14. Gross PL, Fuster BC, Merrill-Skoloff G, Chou J, Fuster B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol 2005;78:1318–1326

15. Fuster BC, Fuster BC. Thrombus formation in vivo. J Clin Invest 2005;115: 3345–3362

16. Gerrits AJ, Koekman CA, Veldhuis J, Nieuwland R, Akkerman JW. Insulin...
inhibits tissue factor expression in monocytes. J Thromb Haemost 2009; 7:198–205
17. Schwertz H, Tolley ND, Fouliks JM, Denis MM, Risemanay BW, Buerke M, Tilley RE, Rondina MT, Harris EM, Kraiss LW, Mackman N, Zimmerman GA, Weyrich AS. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006;203: 2433–2440
18. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977;252:5538–5546
19. Hackeng TM, Hessing M, van ‘t Veer C, Meijer-Huizinga F, Meijers JC, de Groot PG, van Mourik JA, Bouma BN. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993;268:3993–4000
20. Onley DJ, Knight CG, Tuckwell DS, Barnes MJ, Fairdale RW. Micromolar Ca2+ concentrations are essential for Mg2+-dependent binding of collagen by the integrin alpha 2beta 1 in human platelets. J Biol Chem 2000;275:24560–24564
21. Panes O, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007;109: 5242–5250
22. Pillitteri D, Bussus S, Boller K, Mahnel R, Scholz T, Westrup D, Wegert W, Kirchmaier CM. Thrombin-induced interleukin Ibeta synthesis in platelet suspensions: impact of contaminating leukocytes. Platelets 2007;18:119–127
23. Aye MT, Palmer DS, Giuliani A, Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995;35:117–124
24. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20–25
25. Shashkin PN, Brown GT, Ghosh A, McIntyre TM. Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol 2008;181:3495–3502
26. Colwell K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, Duncan PI. The Clik/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 1996;15:265–275
27. Cho MJ, Liu J, Pestina TI, Steward SA, Thomas DW, Coffman TM, Wang D, Jackson CW, Gartner TK. The roles of alpha IIb beta 3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation. Blood 2003;101:2646–2651
28. Cho MJ, Pestina TI, Steward SA, Lowell CA, Jackson CW, Gartner TK. Role of the Src family kinase Lyn in TXA2 production, adenosine diphosphate secretion, Akt phosphorylation, and irreversible aggregation in platelets stimulated with gamma-thrombin. Blood 2002;99:2442–2447
29. Weyrich AS, Denis MM, Schertz H, Tolley ND, Fouliks J, Spencer E, Kraiss LW, Albertine KH, McIntyre TM, Zimmerman GA. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007;109:1975–1983
30. Brogren H, Karlsson L, Anderson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004;104:3943–3948
31. Colwell K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, Duncan PI. The Clik/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 1996;15:265–275